Targeted therapies aimed at modulating androgen receptor activity, such as selective androgen-receptor modulators or androgen-synthesis inhibitors, could represent promising treatment options for patients with hormone receptor-positive breast cancer or for canine mammary tumors. This evidence concerns the gene NR4A1 and breast cancer.